Just What The Doctor Ordered: Hikma Pharmaceuticals Interim Update
Connor Campbell | Aug 10, 2017 11:00
By Connor Campbell, Financial Analyst, Spreadex
Can Hikma Pharmaceuticals (LON:HIK) produce some much needed market medicine with next Thursday’s interim update?
The London-based pharmaceutical firm had a pretty fantastic start to 2017. Approval for a generic Sodium Oxybate oral solution in January, an exclusive Easyhaler licensing and distribution agreement with Finnish drugmaker Orion in February and the US launch of anti-depressant Pristiq in March helped push the higher leading into its full year results.
On 15th March Hikma then spiked 5.5% to a £23-plus 7 month peak after revealing a 35% jump in annual sales to $2 billion. Pre-tax profits, on the other hand, fell by around a third to $210 million following an increase in costs, R&D spending and M&A-related charges. Perhaps most importantly the company announced it was preparing to launch its own version of GlaxoSmithKline's (LON:GSK) superstar asthma drug Advair, a product forecast to account for 15% of the $800 million in revenue expected from its generic division in 2017.
Hikma’s high wasn’t to last long however, as just a day after its annual results JP Morgan downgraded the stock to ‘neutral’ after arguing that the Advair-rival would only provide a short term earnings boost due to a combination of increased competition and generics pricing pressures. This effectively wiped out the growth seen on the day of the full year update, and sparked a long, long decline that Hikma is yet to recover from.
By mid-April the stock was below £19, and though it did bounce to £20 in early May, an update on the 11th of that month soon sent it back to the doghouse. In a massive blow to its plans, the FDA failed to approve its second asthma drug application, the regulator pointing to ‘major’ issues with the application as reason for the rejection.
With chances of approval in 2017 now slim the stock plunged 7.5% on the day of the announcement and then kept falling. A 19th May statement failed to help matters after the company was forced to cut its full year revenue targets from $2.2 billion to a range of $2 billion to $2.1 billion in light of the asthma drug update, with its generics division now expected to generate $670 million in sales.
Since then it’s only been more bad news, as sterling’s recovery against the dollar helped send the multinational company lower. Most recently a note from Morgan Stanley (NYSE:MS), claiming that analysts’ forecasts for the firm hadn’t been sufficiently reined in, lopped off another chunk of value, leaving Hikma Pharmaceuticals at a current trading price, and 3 and a half year low, of £13.10.
In terms of next week’s half year results, the market will be desperate for an update on the asthma drug situation (even if that perhaps seems unlikely). As for hard figures, Hikma is expected to post an 8% increase in revenue to $952.5 million, something which may or may not reassure investors.
Get The App
Hikma Pharmaceuticals PLC has a consensus rating of ‘Hold’ with an average target price of £19.36.
Disclaimer: Spreadex provides an execution only service and the comments above do not constitute (or should not be construed as constituting) investment advice or recommendations, or a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any person placing trades based on their interpretations of the above comments does so entirely at their own risk. Spreadex Ltd is a financial and sports spread betting and sports fixed odds betting firm, which specialises in the personal service and credit area. Founded in 1999, Spreadex is recognised as one of the longest established spread betting firms in the industry with a strong reputation for its high level of customer service and account management.
In relation to spread betting, Spreadex Ltd is authorised and regulated by the Financial Conduct Authority. Spread betting carries a high level of risk to your capital and can result in losses larger than your initial stake/deposit. It may not be suitable for everyone, so please ensure you fully understand the risks involved. In relation to fixed odds, Spreadex Ltd is licensed and regulated by the Gambling Commission under licence number.
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.